Plain-English translation of NCT06567314 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to see if it can help treat two types of cancer: cutaneous squamous cell carcinoma (a type of skin cancer) and castration-resistant prostate cancer (prostate cancer that continues to grow despite hormone treatment). The medication works by helping your immune system recognize and attack cancer cells. Researchers want to learn whether this treatment is effective and safe for people whose cancers have progressed despite other therapies.
Some people with these cancers don't respond well to existing treatments, or their cancer comes back after initial therapy. This medication represents a new approach using the immune system to fight these cancers, and this trial will help doctors understand whether it's a helpful option for patients who need new treatment choices.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive the medication through an IV infusion (into your vein) that takes about 1 to 2 hours, once every 3 weeks. You'll need to visit the clinic regularly for treatment visits and to have blood tests and imaging scans to see how your cancer is responding. The study involves about 24 people total, and your doctors will carefully monitor you for any side effects while collecting information about how well the treatment works.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
M.D. Anderson Cancer Center
Collaborators
Summit Therapeutics
Enrollment target
~24 participants
Started
December 2024
Primary completion
September 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Aung Naing, MD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.